Participants must have an AHI of 15 or higher on polysomnography (PSG) at Day 1 before randomization.
Body Mass Index (BMI) of 27 kg/m\^2 or more at the time of screening.
History of at least one unsuccessful attempt at weight loss through diet and exercise.
Participants must not have used PAP therapy for at least 4 weeks before screening, are unwilling/unable to use PAP, and do not plan to use PAP therapy during the study.
You may not be if
Individuals who have had any previous or planned upper airway surgery or major ear, nose or throat surgery for OSA.
Those with significant craniofacial abnormalities that may affect breathing at screening.
Participants diagnosed with Central or Mixed Sleep Apnea with proportion of mixed or central apneas/hypopneas ≥ 50%, and/or diagnosis of Cheyne Stokes Respiration.
Active device treatment of OSA or other treatments, that in the opinion of the investigator, may interfere with study outcomes.
Individuals with respiratory diseases like obesity hypoventilation syndrome or daytime hypercapnia, neuromuscular diseases or other conditions that could interfere with the trial results, according to the investigator's opinion.
Clareo Health | Maridebart Cafraglutide Versus Placebo in Adult Participants With Obstructive Sleep Apnea Not on Positive Airway Pressure (PAP) Therapy
